More than a century after injectable insulin first saved lives, the U.S. Food and Drug Administration (FDA) has approved a version children can breathe in instead. On 29 May 2026, the agency cleared Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes — making it the first and only inhaled mealtime insulin ever approved for paediatric use anywhere in the world.
What Afrezza Actually Does
Afrezza is not a new molecule. The active ingredient is plain human insulin; what differs is the delivery. MannKind Corporation's proprietary Technosphere platform packages the insulin into microscopic particles that dissolve rapidly in the lungs, pushing insulin into the bloodstream faster than a subcutaneous injection can manage. The idea is to match, more closely, the sharp insulin spike a healthy pancreas produces the moment food arrives — the so-called first-phase response that conventional injections blunt because the drug has to travel through fat tissue first.
For adults, Afrezza has been FDA-approved since 2014. The 29 May decision extends that approval into paediatric territory for the first time, covering both type 1 (the dominant form in children) and type 2 diabetes.
What the INHALE-1 Trial Found
The paediatric approval rests on the Phase 3 INHALE-1 study, a 26-week open-label trial that randomised 230 young patients to either Afrezza or multiple daily injections (MDI) of a rapid-acting insulin analogue combined with basal insulin. The trial enrolled participants aged 4 to 17 — broader than the 6-and-older label the FDA ultimately approved. Of those enrolled, 98% had type 1 diabetes and 2% had type 2.
The primary lung-safety concern — whether inhaling insulin powder could harm developing airways — was directly addressed by spirometry data throughout the trial. At baseline, the Afrezza group recorded a mean forced expiratory volume in one second (FEV1) of 99.6% of predicted; at 26 weeks, that figure was 96.6%. The MDI group moved from 102.3% to 98% predicted over the same period. The difference between arms was not statistically significant, giving regulators confidence that the lung-delivery route does not meaningfully compromise respiratory function in children over a treatment period.
The glycaemic efficacy picture is more nuanced and worth flagging. The pre-specified primary endpoint was HbA1c non-inferiority within a 0.4% margin. On the full intent-to-treat population, Afrezza narrowly missed: the between-group HbA1c difference was 0.435%, just outside that margin. MannKind's analysis attributed the miss largely to one patient who did not adhere to the study protocol. On the modified intent-to-treat population — which excluded that subject — the difference was 0.370%, establishing non-inferiority. The FDA accepted this analysis as sufficient to support approval, but clinicians reviewing the data independently should note the full ITT result and its margin of miss.
The Clinical Case for Going Needle-Free
Needle fear is real and well-documented in paediatric medicine. For a child with type 1 diabetes, managing blood glucose means multiple injections or pump insertions every single day — for life. Adherence gaps compound over years, and poor control in childhood carries consequences that extend into adulthood: cardiovascular disease, kidney damage, retinopathy.
"Children and their families deserve new treatment options that fit the realities of daily life," said MannKind chief executive Michael Castagna in the company's announcement. Dr. Desmond Schatz, Professor of Pediatrics at the University of Florida College of Medicine and a clinician involved in the programme, noted that Afrezza "may help clinicians better match insulin therapy to how children and families live day to day." For eligible patients in the U.S., MannKind stated that Afrezza will be available at US$35 or less per month through its MannKind Cares support programme — a cost point the company (vendor-stated) characterises as designed to remove financial barriers to access.
Why ASEAN Should Pay Attention
The approval is U.S.-specific, but the platform implications reach further. Across South-East Asia, paediatric type 1 diabetes rates are climbing — driven partly by improved diagnosis, partly by genuine incidence increases that researchers are still working to explain. Needle adherence remains a persistent clinical problem in the region, compounded in some markets by cold-chain constraints on injectable biologics, stigma around visible insulin use, and limited specialist paediatric endocrinology capacity outside major city centres.
Pulmonary drug delivery has long attracted attention as a potential equaliser: no sharps disposal, no cold-chain anxiety, discreet use in a school cafeteria. If Technosphere-based inhaled insulin builds a durable safety record in the U.S. paediatric population over the next two to three years, it creates a credible regulatory data package for submissions to ASEAN health agencies — particularly Singapore's Health Sciences Authority, Malaysia's National Pharmaceutical Regulatory Agency, and the Thai FDA, all of which typically follow U.S./EU approval precedents when evaluating novel delivery platforms. That pathway is speculative for now, but the FDA's willingness to approve an inhaled biologic for children signals that pulmonary delivery has moved from niche to mainstream consideration.
Caveats and Ongoing Monitoring
Afrezza carries a prescribing requirement for lung-function assessment before treatment begins, at six months, and annually thereafter. The drug is contraindicated in patients with chronic lung disease such as asthma or chronic obstructive pulmonary disease — a restriction that limits its use in a subset of children. Longer-term respiratory data beyond 26 weeks in paediatric patients is still being gathered; clinicians will want to track FEV1 trends across full adolescent development. The INHALE-1 results are expected to be presented at an upcoming ISPAD (International Society for Pediatric and Adolescent Diabetes) conference, which will allow independent scrutiny of the full dataset.
View author profile → · Editorial policy
